Intravenous bisphosphonates;Bisfosfonatos intravenosos

Medicina Clinica

Volumn 124, Issue 9, 2005, Pages 348-354

  Hernández Hernández, José Luis ^a   Riancho Moral, José Antonio ^a   González Macías, Jesús ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Biphosphonates; Hypercalcemia; Intravenous; Neoplasms; Osteoporosis; Paget's disease of bone; Transplantation

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; IBANDRONIC ACID; NERIDRONIC ACID; PAMIDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE MINERAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG ABSORPTION; ESOPHAGUS INJURY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPERCALCEMIA OF MALIGNANCY; METABOLIC BONE DISEASE; METASTASIS; ORGAN TRANSPLANTATION; PAGET BONE DISEASE; PATHOLOGIC FRACTURE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; OSTEOPOROSIS;

DIPHOSPHONATES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; OSTEOPOROSIS;

EID: 19044367541     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13072425     Document Type: Review

References (79)

1. Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc. 2002;77:1031-43.
2. Pelayo M, Agra Y. Bisfosfonatos en la prevención de la osteoporosis de mujeres posmenopáusicas con baja masa ósea. Med Clin (Barc). 2004; 122:304-10.
3. Arboleya LR, Morales A, Fiter J. Efecto del alendronato sobre la densidad minereral ósea y la incidencia de fracturas en mujeres posmenopáusicas con osteoporosis. Un metaanálisis de los estudios publicados. Med Clin (Barc). 2000;14:79-84.
4. Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol. 2002;29:12-8.
5. Body JJ. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer. 2003;97:859-65.
6. Coleman RE. Bisphosphonates for the prevention of bone metastases. Semin Oncol. 2002;29:43-9.
7. Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med. 1998;104:459-69.
8. Delmas PD, Meunier PJ. The management of Paget's disease of bone. N Engl J Med. 1997;336:558-66.
9. Watts NB. Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am. 2001;27:197-214.
10. Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 2000;29:228-51.
11. Body JJ. Hypercalcemia of malignancy. Semin Nephrol. 2004;24:48-54.
12. Atula ST, Tahtela RK, Nevalainen JI, Pylkkanen LH. Clodronate as a single-dose intravenous infusion effectively provides short-term correction of malignant hypercalcemia. Acta Oncol. 2003;42:735-40.
13. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer. 1995;72:1289-93.
14. Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med. 1993;95:297-304.
15. Ralston SH, Thiebaud D, Herrmann Z, Steinhauer EU, Thurlimann B, Walls J, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer. 1997;75:295-300.
16. Major PP, Coleman RE. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol. 2001;28:17-24.
17. Pecherstorfer M, Steinhauer EU, Rizzoli R, Wetterwald M, Bergstrom B. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer. 2003;11:539-47.
18. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev. 2002;2:CD002068.
19. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21:4277-84.
20. Wellington K, Goa KL. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs. 2003;63:417-37.
21. Kanis JA, Powles T, Paterson AHG, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 1996;19:663-7.
22. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:488-530.
23. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996;335:1785-91.
24. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91:1191-2000.
25. Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100:36-43.
26. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150-7.
27. Menssen HD, Sakalova A, Fontana A, Herrmann Z, Boewer C, Facon T, et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol. 2002;20:2353-9.
28. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SR. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ. 2003;327;469-74.
29. Ross JR, Saunders Y, Edmonds PM, Patel S, Wonderling D, Normand C, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess. 2004;8:1-176.
30. Filipponi P, Cristallini S, Policani G, Schifini MF, Casciari C, Garinei P. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass. Bone. 2000;26:269-74.
31. Filipponi P, Pedetti M, Fedeli L, Cini L, Palumbo R, Boldrini S, et al. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res. 1995;10:697-703.
32. Filipponi P, Cristallini S, Rizzello E, Policani G, Fedeli L, Gregorio F, et al. Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. Bone. 1996;18:179-84.
33. Heikkinen JE, Selander KS, Laitinen K, Arnala I, Vaananen HK. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss. J Bone Miner Res. 1997;12:110-3.
34. Peretz A, Body JJ, Dumon JC, Rozenberg S, Hotimski A, Praet JP, et al. Cyclical pamidronate infusion in postmenopausal osteoporosis. Maturitas. 1996;25:69-75.
35. Morabito N, Gaudio A, Lasco A, Vergara C, Tallarida F, Crisafulli G, et al. Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis. Osteoporos Int. 2003;14:500-6.
36. Heijckmann AC, Juttmann JR, Wolffenbuttel BH. Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. Neth J Med. 2002;60:315-9.
37. Steelman J, Zeitler P. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr. 2003;142:417-23.
38. Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int. 1997;61:266-71.
39. Kim SH, Lim SK, Hahn JS. Effect of pamidronato on new vertebral fractures and bone mineral density in patients with malignant lymphoma receiving chemotherapy. Am J Med. 2004;116:524-8.
40. Rastelli A, Napoli N, Civitelli R. Intravenous pamidronate increases bone density in postmenopausal women previously treated with oral bisphosphonates [resumen]. ASBMR 2003.
41. Vasikaran SD, Khan S, McCloskey EV, Kanis JA. Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone. 1995; 17:517-20.
42. Khan SA, Kanis JA, Vasikaran S, Kline WF. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res. 1997;12:1700-7.
43. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res. 2000;15:599-604.
44. Braga V, Gatti D, Colapietro F, Battaglia E. Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone. 2003;33:342-5.
45. Thiebaud D, Burkhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med. 1997;103:298-307.
46. Schimmer RC, Bauss F. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther. 2003;25:19-34.
47. Stakkestad JA, Benevolenskaya L, Stepan JJ, Skag A, Nordby A, Oefjord E, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis. 2003;62:969-75.
48. Ringe JD, Dorst A, Faber H, Ibach K, Preuss J. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxford). 2003;42:743-9.
49. Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int. 2003;14:801-7.
50. Adachi JD, Christiansen C, Stakkestad JA, McClung M, Burdeska A, Mahoney P, et al. Both oral and intravenous ibandronate effectively prevent postmenopausal bone loss in women without osteoporosis. J Bone Miner Res. 2003;18(Suppl 2):5372.
51. Recker R, Stakkestad J, Chesnut CH III, Christiansen C, Skag A, Hoiseth A, et al. Insufficiently dosed intravenous ibandronato injections are associated with suboptimal antfracture efficacy in postmenopausal osteoporosis. Bone. 2004;34:890-9.
52. Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, et al. Efficacy and safety of ibandronato given by intravenous injection once every 3 months. Bone. 2004;34:881-9.
53. Miller PD, Recker RR, Adami S, Bonvoisin B, Schimmer RC. Rationale for intermittent intravenous ibandronate injections in postmenopausal osteoporosis. J Bone Miner Res. 2003;18(Suppl 2):5263.
54. Lamy O, Sandini L, Pache I, Fatio S, Burnand J, Burckhardt P. Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years. J Endocrinol Invest. 2003;26:728-32.
55. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-61.
56. Mikulec KH, Delaney MF, Hurwitz S, LeBoff MS. Safety and efficacy of zoledronico acid: a chart review [resumen]. ASBMR 2003.
57. Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int. 2003;14:617-30.
58. Dodidou P, Bruckner T, Hosch S, Haass M, Klar E, Sauer P, et al. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int. 2003;14:82-9.
59. Aris RM, Lester GE, Renner JB, Winders A, Denene Blackwood A, Lark RK, et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med. 2000; 162:941-6.
60. Fan SL, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int. 2000;57:684-90.
61. Nam JH, Moon JI, Chung SS, Kim SI, Park KI, Song YD, et al. Pamidronate and calcitriol trial for the prevention of early bone loss alter renal transplantation. Transplant Proc. 2000;32:1876.
62. Ninkovic M, Love S, Tom BD, Bearcroft PW, Alexander GJ, Compston JE. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol. 2002;37:93-100.
63. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. 2003;63:1130-6.
64. Delmas PD, Chapuy MC, Vignon E. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metab. 1982;54:837-44.
65. Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ. Effect of multiple intravenous pamidronate courses in Paget's disease of bone. Rev Rhum Engl Ed. 1999;66:467-76.
66. Watts RA, Skingle SJ, Bhambhani MM, Pountain G, Crisp AJ. Treatment of Paget's disease of bone with single dose intravenous pamidronate. Ann Rheum Dis. 1993;52:616-8.
67. Tucci JR, Bontha S. Intravenously administered pamidronate in the treatment of Paget's disease of bone. Endocr Pract. 2001;7:423-9.
68. Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to the diagnosis and management of Paget's disease of bone. J Bone Miner Res. 2001;16:1379-87.
69. Buckler H, Fraser W, Hosking D, Ryan W, Maricic MJ, Singer F, et al. Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study. Bone. 1999;24(5 Suppl):81-5.
70. Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, et al. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics. 2003;111:573-8.
71. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-52.
72. Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res. 2003;18:126-30.
73. Arikoski P, Silverwood B, Tillmann V, Bishop NJ. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone. 2004;34:539-46.
74. Zacharin M, O'Sullivan M. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J Pediatr. 2000;137:403-9.
75. Robinson C, Baker N, Noble J, King A, David G, Sillence D, et al. The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment. J Inherit Metab Dis. 2002;25:681-93.
76. Reid IR. Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol. 2003;15:458-63.
77. Cohen SB. An update on bisphosphonates. Curr Rheumatol Rep 2004; 6:59-65.
78. Peter R, Mishra V, Fraser WD. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ. 2004;328:335-6.
79. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003;349:457-63.